Answers are grounded in this paper and cite their sources.
Head and neck squamous cancers (HNSC) are a group of heterogeneous tumors that frequently have TP53 mutations associated with a worse prognosis and poor response to treatment. Current therapy combines chemotherapy and radiotherapy for both early and advanced diseases, underscoring the need for new drugs to improve conventional therapy. In recent years, natural product research has increasingly focused on the discovery and development of anticancer agents. Dicentrine (1), for example, is an aporphine alkaloid isolated from the leaves of Ocotea puberula. Dicentrine and its N-oxide derivatives (compounds 1a and 1b) have demonstrated cytotoxic activity against tumor cells, highlighting their potential as bioactive natural-product scaffolds. As a continuation of our studies, the present work investigated the antitumor potential of compounds 1, 1a, and 1b in head and neck squamous cell carcinoma (HNSCC) cell lines with distinct TP53 statuses, namely, FaDu (TP53 mutant) and SCC143 (TP53 wild-type) cells. In vitro studies through cell viability, colony formation assay, cell death, and in silico analysis through molecular docking and molecular dynamics simulations demonstrated that compound 1b has lost its antitumor activity, while compounds 1 and 1a inhibited colony formation, decreased cell viability, and induced cell death independently of TP53 status. We also demonstrated that compounds 1 and 1a decreased HMGB1, IL18, and Akt expression. Our in silico analysis suggested that compounds 1 and 1a adopt a productive binding mode at the AKT1 kinase, whereas p53 is not a stable target. Such findings provide additional evidence for the use of compounds 1 and 1a as therapeutic drugs also for head and neck cancer.
No takes yet. Share an insight, caveat, or question.
Araújo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: